Clinical trials report

Efficacy and safety of cholesterol lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomized trials of statins. Cholesterol Treatment Trialists (CTT) Collaborators. Lancet 2005, 366:1267–1278. The Lipid Research Clinics coronary primary prevention trial results. Reduction in incidence of coronary heart disease. (LRC-CPPT). JAMA 1984, 251:351–364. Buchwald H, Varco RL, Matts JP, et al.: Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. Report on the Program on the Surgical Control of Hyerlipidemia (POSCH). N Engl J Med 1990, 323:946–955. Ornish D, Brown SE, Scherwitz LW, et al.: Can lifestyle changes reverse coronary heart disease? Lancet 1990, 336:129–133. Brown G, Albers J, Fisher L, et al.: Regression of coronary artery disease as a result of intensive lipid lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990, 323:1289–1298. Davidson MH, McGarry T, Bettis R, et al.: Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J Am Coll Cardiol 2002, 40:2125–2134. Wiegman A, de Groot E, Hutton BA, et al.: Arterial intima-media thickness in children heterozygous for familial hypercholesterolemia. Lancet 2004, 363:369–370. Robinson JG, Smith B, Maheshwari N, et al.: Pleiotropic effects of statins: benefit beyond cholesterol reduction? A meta-regression analysis. J Am Coll Cardiol 2005, 46:1855–1862. Howard G, Sharrett AR, Heiss G, et al.: Carotid artery intimal-medial thickness distribution in general population as evaluated by B-mode ultrasound. Stroke 1993, 24:1297–1304. Kastelein JJ, van Leuven SI, Burgess I, et al.: Effects of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med 2007, 356:1620–1630. Nissen SE, Tardif JC, Nicholls SJ, et al.: Effect of torcetrapib on the progression of coronary atherosclerosis (ILLUSTRATE). N Engl J Med 2007, 356:1304–1316. Smilde T, van Wissen S, Wollersheim H, et al.: Effect of aggressive versus conventional lipid lowering on atherosclerotic progression in familial hyperdholeseterolemia (ASAP). Lancet 2001, 357:577–581. Brown BG, Taylor AJ: Does ENHANCE diminish confidence in lowering LDL-C or in ezetimibe? N Engl J Med 2008, 358:1504–1507. Nissen SE, Tuzcu EM, Schoenhagen R, et al.: Effect of intensive compared to moderate lipid lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 2004, 291:1071–1080. Nissen SE, Nicholls SJ, Sipahi I, et al.: Effect of very high intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 2006, 295:1556–1565. Results From The SEAS (Simvastatin And Ezetimibe In Aortic Stenosis) Study. Available at: http://www.medicalnewstoday.com/articles/115715.php. Accessed July 22, 2008. IMPROVE-IT: examining outcomes in subjects with acute coronary syndrome: Ezetimibe/simvastatin vs simvastatin study (P04103). Available at: http://clinicaltrials.gov/ct2/show/NCT00202878. Accessed July 22, 2008. American College of Cardiology statement on ENHANCE trial. Available at: http://www.acc.org/enhance.htm. Accessed on July 22, 2008. Krum H, McMurray JJ: Statins and chronic heart failure: do we need a large scale outcome trial? J Am Coll Cardiol 2002, 39:1567–1573. Cleland JG, Loh H, Windram J, et al.: Threats, opportunities and statins in the modern management of heart failure. Eur Heart J 2006, 27:641–643. Rauchhaus M, Clark A, Doehner W, et al.: The relationship between cholesterol and survival in patients with chronic heart failure. J Am Coll Cardiol 2003, 42:1933–1940. Uretsky BF, Tygesen K, Armstrong P, et al.: Acute coronary findings at autopsy in heart failure patients with sudden death: results from the assessment of treatment with lisinopril and survival (ATLAS) trial. Circulation 2000, 102:611–616. Levabtesi G, Scarano M, Marfisi RM, et al.: Meta-analysis of effect of statin treatment on risk of sudden death. Am J Cardiol 2007, 100:1644–1650. Wojnicz R, Wilczek K, Kozielska E, et al.: Usefulness of atorvastatin in patients with heart failure due to inflammatory dilated cardiomyopathy and elevated cholesterol levels. Am J Cardiol 2007, 97:899–904. Fukuta H, Sane D, Brucks S, et al.: Statin therapy may be associated with lower mortality in patients with diastolic heart failure. Circulation 2005, 112:357–363. Marzcoff L, Thompson P: The role of coenzyme Q10 in statin associated myopathy: a systematic review. J Am Coll Cardiol 2007, 49:2231–2237. van Jaarsveld CH, Ranchor AV, Kempen GI, et al.: Epidemiology of heart failure in community based study of subjects aged > 57 years. Eur Heart J 2006, 8:23–30. The CONSESUS Trial Study Group: Effects of enalapril on mortality in severe congestive heart failure. N Engl J Med 1987, 316:1429–1435. Wild S, Roglic G, Green A, et al.: Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004, 27:1047–1053. Stamler J, Vaccaro O, Neaton JD, et al.: Diabetes, other risk factors, and 12 year cardiovascular mortality in men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993, 16:434–444. Snow V, Aronson MD, Hornbake ER, et al.: Lipid control in the management of type 2 diabetes mellitus: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2004, 140:644–649. Cholesterol Treatment Trialist (CTT) Collaborators: Efficacy and safety of cholesterol lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomized trials of statins. Lancet 2006, 368:1267–1278. Clearfield M: Clinical trials report. Curr Atheroscler Rep 2007, 9:8–9. Grundy SM, Cleeman JI, Merz NB, et al.: Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004, 110:227–239. Statins for the Prevention of Cardiovascular Events (technology Appraisal 94). London: National Institute of Healthcare and Clinical Excellence; 2006. Knopp RH, d’Emden, Smilde JG, et al.: Efficacy and safety of atorvastatin in the prevention of cardiovascular endpoints in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease in non-insulin dependent diabetes (ASPEN). Diabetes Care 2006, 29:1478–1485. Wanner C, Krane V, Marz W, et al.: Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005, 353:238–248.